Tech Company Financing Transactions
EyeBio Funding Round
Bain Capital Life Sciences, Jeito Capital and MRL Ventures participated in a $65 million Series A funding round for EyeBio. The round closed on 11/14/2023.
Transaction Overview
Company Name
Announced On
11/14/2023
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the proceeds from the funding to accelerate its clinical development program and further build out its innovative retina pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
International Building 71 Kingsway
London, England, WC2B 6ST
UK
London, England, WC2B 6ST
UK
Phone
Undisclosed
Website
Email Address
Overview
EyeBio is a clinical-stage ophthalmology biotech company that brings together an experienced team of leaders, innovators, and entrepreneurs to develop a new generation of therapies for eye diseases. We understand what it takes to establish a new standard of care in ophthalmology. Our co-founders, Dr. David Guyer and Dr. Anthony P. Adamis, created and led the company that introduced the first anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Guyer
Chief Technical Officer
Joost Ouwerkerk
Co-Founder
Fred Lalonde
Co-Founder
Laurence Tosi
Browse more venture capital transactions:
Prev: 11/14/2023: AristaMD venture capital transaction
Next: 11/14/2023: Aikido Security venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs